A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma.
Christina Bennett, MS
Advertisement
Articles by Christina Bennett, MS
Researchers conducted a cost-effectiveness analysis on the two FDA-approved CAR T-cell therapies for diffuse large B-cell lymphoma.
Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.
A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.
Advertisement
Latest Updated Articles
Cost Effectiveness of CAR T-Cell Therapy Depends on Long-Term OutcomesPublished: June 23rd 2019 | Updated:
For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy ExcitesPublished: April 9th 2019 | Updated:
Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer PatientsPublished: July 11th 2019 | Updated:
Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid TumorsPublished: April 10th 2019 | Updated:
